Industry
Biotechnology
Topic
Mergers and Acquisitions
People
Find news about people
Organizations
Find news about organizations
Alumni
Find news on alumni of any org
Your Contacts
Find news on your contacts
Sign up for free daily alerts on this feed:
By pressing Sign Up, you agree to our Terms of Use, Privacy Policy, and the LexisNexis Terms & Conditions

Follow

Change Feed
Mergers and Acquisitions in Biotechnology
... French drugmaker Sanofi is close to acquiring biotechnology company Bioverativ for $105 a share, valuing the maker of hemophilia drugs at about ...
... Sanofi SA is nearing a deal to buy hemophilia drugmaker Bioverativ Inc. for more than $11.5 billion as the French drugmaker looks set ...
... out that no one is immune from the risk of seller’s remorse. Juno Therapeutics chief executive officer Hans Bishop sold about 270,000 shares of company ...
... ORIGINAL ANNOUNCEMENT [Text] VICTORIA, British Columbia, Jan. 18, 2018 -- IMMUNOPRECISE ANTIBODIES LTD. (the "Company") (TSX VENTURE: IPA)(OTC PINK: IPATF) announces that it has engaged ...
... A buyout of Juno Therapeutics could help Celgene diversify its drug portfolio as its No. 1 ...
... Chemical and the Reference Petrochemical Advantages of Renewable Chemicals 5. PRODUCT INTRODUCTIONS/INNOVATIONS Genomatica Launches GENO BG(TM) Biobased Process Technology Eastman Launches Eastman TREVA(TM) Engineering Bioplastic ...
... Amgen (NASDAQ: AMGN) and Allergan plc. (NYSE: AGN) today announced that the European Commission ...
... of approximately $6.809M of common stock Completion of transaction anticipated to allow Xtant to meet liquidity needs and reposition itself for long-term growth. BELGRADE, Mont., ...
... heads the Life Sciences team. His portfolio includes companies like Flatiron Health, 23andMe, and LifeMine Therapeutics. Yeshwant was drawn to venture capital after seeing the ...
... purchases will solve anything. The biotech giant is in talks to acquire Juno Therapeutics , JUNO 49.50% The Wall Street Journal reported Tuesday. This comes ...
... CANADIAN DAILY STOCK REPORT Immunoprecise Antibodies Ltd. (TSXV:IPA) has dropped 2.0c (3.1%) from its last trading session of ...
... YORK (AP) - Stocks that moved substantially or traded heavily Wednesday: Juno Therapeutics Inc., up $23.65 to $69.25 The Wall Street Journal reported that biotech ...
... WALTHAM, Mass., Jan. 17, 2018 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq:NURO) announced today a collaboration with GlaxoSmithKline (NYSE:GSK), one of the ...
... care convention. Winners Coming in first in terms of stock performance was Atara Biotherapeutics, up 52 percent since the start of 2018. Most of its ...
... another biotech company. The Summit, New Jersey-based company is looking to purchase Juno Therapeutics, just one week after it announced that it was taking over ...
... CANADIAN DAILY STOCK REPORT Liberty Biopharma Inc. (TSXV:LTY), Canada's 30th largest Biotechnology company by market cap, has risen ...
... AMP Capital has acquired a 21 per cent stake in the Victorian Comprehensive Cancer Centre (VCCC) building from funds managed and/or advised by Partners Group ...
... LIQUID MEDIA GROUP, INC.: Acquires 51% of Majesco Entertainment Company, and Announces $4,000,000 US Preferred Share Subscription VANCOUVER, British Columbia, Jan. ...
... CANADIAN DAILY STOCK REPORT Immunoprecise Antibodies Ltd. (TSXV:IPA) extended its gains on Friday, rising an additional 1.0c (1.5%) ...
... CANADIAN DAILY STOCK REPORT Liberty Biopharma Inc. (TSXV:LTY), Canada's 29th largest Biotechnology company by market cap, has tumbled ...
... Charles River Laboratories International, Inc. (NYSE: CRL) today announced that it has acquired KWS BioTest, a ...
... Acquisition VANCOUVER, British Columbia, Nov. 16, 2017 -- Calyx Bio-Ventures Inc. (TSX-V:CYX) ("Calyx" or the "Company") is pleased to announce that it has acquired Canada ...
... CANADIAN DAILY STOCK REPORT Liberty Biopharma Inc. (TSXV:LTY), Canada's 36th largest Biotechnology company by market cap, has lifted ...
... CANADIAN DAILY STOCK REPORT Immunoprecise Antibodies Ltd. (TSXV:IPA), was unchanged after hitting the upper Bollinger Band four times ...
... million and is expanding its experimental Alzheimer's portfolio through a collaboration with Denali Therapeutics. The Denali deal is worth up to more than $1 billion. ...
... Zymergen, a molecular technology company integrating machine learning and manufacturing technologies to engineer ...
... purchase of certain assets from i2 Pharmaceuticals and its affiliates, further strengthening Editas' guide RNA chemistry capabilities and intellectual property Provides updates on advancements in ...
... Amgen (NASDAQ:AMGN) and UCB (Euronext Brussels: UCB) today announced that the European Medicines ...
Want to see the full history on Mergers and Acquisitions in Biotechnology? Upgrade to RelSci Pro now!
Start My Free Trial